Veru

Veru

Yahoo Finance • 17 days ago

Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients

Earnings Call Insights: Veru Inc. (VERU) Q3 fiscal 2026 MANAGEMENT VIEW * Dr. Mitchell Steiner said Veru is focused on two small molecules, with near-term emphasis on enobosarm in obesity: enobosarm is being developed “as a next-genera... Full story

Yahoo Finance • 17 days ago

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calenda... Full story

Yahoo Finance • 18 days ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Barrick Mining Corporation (B [https://seekingalpha.com/symbol/B]) * Medical Properties Trust (MPT [https://seekingalpha.com/symbol/MPT]) * Seadrill Limited (SDRL [https:/... Full story

Yahoo Finance • last month

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical sta... Full story

Yahoo Finance • 2 months ago

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • 3 months ago

Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wego... Full story

Yahoo Finance • 3 months ago

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027— --Company to host conference call and webcast today at 8:00 a.m. ET— MIAMI, FL... Full story

Yahoo Finance • 6 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seekingalpha.com/symbol/MCD]) * The Kraft Heinz Company (KHC [https://seeki... Full story

Yahoo Finance • 7 months ago

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • 8 months ago

Earnings week ahead: FDX, NKE, MU, BB, CCL, ACN, and more

[Business.] artisteer/iStock via Getty Images The upcoming week may be a quiet one for earnings reports, but several notable companies are poised to grab investor attention. Tech stalwart BlackBerry (BB [https://seekingalpha.com/symbol/B... Full story

Yahoo Finance • 10 months ago

Veru Announces Proposed Public Offering

MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced t... Full story

Yahoo Finance • 11 months ago

Onconetix announces financing through private placement, debt settlement

Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shar... Full story

Yahoo Finance • 11 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story

Yahoo Finance • last year

Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment

Earnings Call Insights: Veru Inc. (VERU) Q3 2025 MANAGEMENT VIEW * CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, emphasizing two c... Full story

Yahoo Finance • last year

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-... Full story

Yahoo Finance • last year

Veru Q3 2025 Earnings Preview

* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) is scheduled to announce Q3 earnings results on Tuesday, August 12th, before market open. * The consensus EPS Estimate is -$0.50 [https://seekingalpha.com/symbol/VERU/earnings... Full story

Yahoo Finance • last year

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story

Yahoo Finance • last year

Veru announces 1-for-10 reverse stock split

* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) on Wednesday announced a reverse stock split at a ratio of 1-for-10, effective August 11, 2025. * At the effective time, all outstanding stock options, stock appreciation righ... Full story

Yahoo Finance • last year

Veru Announces Reverse Stock Split

MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • last year

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story